Th17 cells: A new target in kidney disease research

Zhang, Tao; Huo, Hongyan; Zhang, Yinghui; Tao, Jie; Yang, Junzheng; Rong, Xianglu; Yang, Yiqi

doi:10.1080/08830185.2024.2321901

International Reviews of Immunology

2024

DOI: 10.1080/08830185.2024.2321901

|View full text |Cite

Th17 cells: A new target in kidney disease research

Tao Zhang,

Hongyan Huo,

Yinghui Zhang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lupus Nephritis from Pathogenesis to New Therapies: An Update

Roveta,

Parodi,

Brezzi

et al. 2024

IJMS

View full text Add to dashboard Cite

Lupus Nephritis (LN) still represents one of the most severe complications of Systemic Lupus Erythematosus (SLE) and a major risk factor for morbidity and mortality. However, over the last few years, several studies have paved the way for a deeper understanding of its pathogenetic mechanisms and more targeted treatments. This review aims to provide a comprehensive update on progress on several key aspects in this setting: pathogenetic mechanisms of LN, including new insight into the role of autoantibodies, complement, vitamin D deficiency, and interaction between infiltrating immune cells and kidney resident ones; the evolving role of renal biopsy and biomarkers, which may integrate information from renal histology; newly approved drugs such as voclosporin (VOC) and belimumab (BEL), allowing a more articulate strategy for induction therapy, and other promising phase III-immunosuppressive (IS) agents in the pipeline. Several adjunctive treatments aimed at reducing cardiovascular risk and progression of chronic renal damage, such as antiproteinuric agents, represent an important complement to IS therapy. Furthermore, non-pharmacological measures concerning general lifestyle and diet should also be adopted when managing LN. Integrating these therapeutic areas requires an effort towards a holistic and multidisciplinary approach. At the same time, the availability of an increasingly wider armamentarium may translate into improvements in patient’s renal outcomes over the next decades.

show abstract

Lupus Nephritis from Pathogenesis to New Therapies: An Update

Roveta,

Parodi,

Brezzi

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Th17 cells: A new target in kidney disease research

Cited by 1 publication

References 186 publications

Lupus Nephritis from Pathogenesis to New Therapies: An Update

Lupus Nephritis from Pathogenesis to New Therapies: An Update

Contact Info

Product

Resources

About